OM Outset Medical

Outset Medical to Present at the 41st Annual J.P. Morgan Healthcare Conference

SAN JOSE, Calif.--(BUSINESS WIRE)--

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 11:15am PT / 2:15pm ET.

A live and archived webcast of the presentation will be available on the “Investors” section of the Outset website at .

About Outset Medical, Inc.

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.

EN
20/12/2022

Underlying

OMOutset Medical

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Outset Medical

 PRESS RELEASE
Free
OM OUTSET MEDICAL

Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635...

Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN JOSE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company’s Inducement Plan, as a material inducement to employment to Derick Elliott, the Company’s newly appointed Executive Vice President of Commercial, as well a...

April 8, 2026 1 EN
 PRESS RELEASE
Free
OM OUTSET MEDICAL

Outset Medical Names Derick Elliott as Executive Vice President of Com...

Outset Medical Names Derick Elliott as Executive Vice President of Commercial SAN JOSE, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced the appointment of Derick Elliott as Executive Vice President of Commercial, effective immediately. Mr. Elliott is responsible for Outset’s commercial organizations supporting acute, post-acute and home healthcare providers, reporting to Chair and CEO Leslie Trigg. He ...

April 6, 2026 1 EN
 PRESS RELEASE
Free
OM OUTSET MEDICAL

Outset Medical Reports Fourth Quarter and Full Year 2025 Financial Res...

Outset Medical Reports Fourth Quarter and Full Year 2025 Financial Results SAN JOSE, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter, Year-End and Recent Highlights Net revenue totaled $28.9 million in the fourth quarter, bringing revenue in 2025 to $119.5 million, a 5% increase over $113.7 million in 2024.Recurring revenu...

February 11, 2026 1 EN
 PRESS RELEASE
Free
OM OUTSET MEDICAL

Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Seco...

Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned Tablo becomes first dialysis system to clear FDA’s most rigorous cybersecurity standards SAN JOSE, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) of its next-generation Tablo platform, designed to deliver enterprise-level security, reliability ...

January 27, 2026 1 EN
 PRESS RELEASE
Free
OM OUTSET MEDICAL

Outset Medical to Report Fourth Quarter 2025 Financial Results on Wedn...

Outset Medical to Report Fourth Quarter 2025 Financial Results on Wednesday, February 11, 2026 SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2025 after the close of trading on Wednesday, February 11, 2026. On the same day, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Rene...

January 26, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch